How GLP-1 and GIP medications affect colonoscopy bowel cleansing
Official title: The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial
Run by The Cleveland Clinic · NCT07127354 · Data updated 2026-11-12
This test will see if taking GLP‑1 or GIP medications affects bowel cleansing for adults getting an outpatient colonoscopy.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 132 (estimated) |
| Sponsor | The Cleveland Clinic Academic / other |
| Locations | 3 sites (Cleveland, Florida and 2 other locations) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | August 2026 |
| Study ends | August 2026 |
| Registry record updated | December 4, 2025 |
| Trial ID | NCT07127354 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 or older scheduled for an outpatient screening, surveillance, or diagnostic colonoscopy who have been on a stable dose of a GLP‑1 or GIP agonist for at least one month and can follow the prescribed bowel prep are ideal candidates.
✕Probably not a fit
Patients with other major risk factors for poor bowel preparation, those who refuse the recommended bowel prep regimen, or those unable to provide informed consent are unlikely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 4 trial will enroll adults on a stable dose of a GLP‑1 or GIP agonist who are scheduled for outpatient colonoscopy. Participants will either hold or continue a single pre-procedure dose of their GLP‑1/GIP medication while following the USMSTF-recommended bowel preparation regimen. The study will compare rates of inadequate bowel preparation and record any complications such as gastric aspiration between the groups. All procedures and follow-up visits will occur at Cleveland Clinic sites in Florida.
Why it matters
Potential benefit: If positive, the results could give clear guidance on whether withholding GLP‑1/GIP before colonoscopy improves cleansing and reduces the need for repeat procedures.
How similar studies have gone: Existing evidence is mostly case reports and observational data linking GLP‑1 agonists to delayed gastric emptying, while randomized or large comparative data on colonoscopy prep quality are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (Age 18 years or older) * Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy * Using a GLP-1 or GIP agonist at a stable dose for at least one month Exclusion Criteria: * Unable to provide informed consent, e.g., dementia * Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy) * Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater: 1. Cirrhosis 2. Parkinson's disease 3. Dementia 4. Tricyclic antidepressant use 5. Opioid use 6. Gastroparesis\* or suspected gastric outlet obstruction on pre-procedure imaging (\*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy) 7. Previous colorectal surgery 8. Prior history of inadequate bowel preparation
Where it's running
-
Cleveland Clinic
Cleveland, Florida, United States Recruiting -
Cleveland Clinic
Cleveland, Florida, United States Recruiting -
Cleveland Clinic Weston
Weston, Florida, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ubiquinol to See if It Reduces Fatigue for Adults Using GLP-1 Weight-Loss Meds
A daily ubiquinol supplement is tested to see if it lowers fatigue and helps keep muscle strength in adults taking GLP-1 weight-loss medicines.
-
Discontinuation timing of GLP-1 receptor agonists before colonoscopy
This study tests whether stopping GLP-1 receptor agonists for either 0 or 7 days before colonoscopy affects bowel prep quality and the need for a repeat procedure in adults undergoing colonoscopy.
-
Should GLP-1 receptor agonists be stopped a week before an endoscopy?
A one-week pause of long-acting GLP-1 receptor agonists is being tested to see if it improves gastric prep quality and reduces the need for repeat endoscopy in adults undergoing EGD.
-
Thirst-Relief Kit vs Placebo to Ease Thirst During Colorectal Prep for Colonoscopy
A thirst-relief kit containing a lemon popsicle is being tested to see if it lowers thirst and improves comfort for adults undergoing hospital bowel preparation for colonoscopy, compared with a placebo.
-
Individualized, non-drug prep to improve bowel cleaning for colonoscopy
This trial tests whether an individualized non-pharmacological plan—plus tailored information framing—can improve bowel preparation quality for adults undergoing colonoscopy.
-
GLP-1 receptor agonists and dry eye in adults with type 2 diabetes and obesity
This study tests whether GLP-1 receptor agonists affect dry eye disease in adults with type 2 diabetes and obesity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.